title: Retreatment and maintenance therapy with infliximab in fistulizing Crohn's disease.
authors.affiliation: Service of Digestive Diseases, Hospital Central de Asturias, Oviedo, Spain. lrodrigos@terra.es
authors.forename: L
authors.initials: L
authors.lastname: Rodrigo
authors.forename: J M
authors.initials: JM
authors.lastname: Pérez-Pariente
authors.forename: D
authors.initials: D
authors.lastname: Fuentes
authors.forename: V
authors.initials: V
authors.lastname: Cadahia
authors.forename: A
authors.initials: A
authors.lastname: García-Carbonero
authors.forename: P
authors.initials: P
authors.lastname: Niño
authors.forename: R
authors.initials: R
authors.lastname: de Francisco
authors.forename: R
authors.initials: R
authors.lastname: Tojo
authors.forename: M
authors.initials: M
authors.lastname: Moreno
authors.forename: E
authors.initials: E
authors.lastname: González-Ballina
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000465:Algorithms; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003424:Crohn Disease / Q000150:complications / Q000188:drug therapy*; D005260:Female; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D000069285:Infliximab; D007412:Intestinal Fistula / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D019233:Retreatment; D013997:Time Factors
chemical_list: D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D000069285:Infliximab